/ELAN
ELAN Stock - Elanco Animal Health Incorporated
Healthcare|Drug Manufacturers - Specialty & GenericNYSE
$22.30+0.95%
+$0.21 (+0.95%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.84
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).83
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.46
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.6%upside
Target: $26.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELAN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$22.08 – $22.52
TARGET (TP)$26.00
STOP LOSS$20.52
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.86
52W High$23.70
52W Low$8.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.44B | $4.42B | $4.41B | $4.76B | $3.27B |
| Gross Profit | $1.91B | $1.94B | $1.97B | $2.08B | $1.25B |
| Gross Margin | 43.0% | 43.9% | 44.7% | 43.6% | 38.1% |
| Operating Income | $251.00M | $326.00M | $384.00M | $304.00M | $-76,800,000 |
| Net Income | $338.00M | $-1,231,000,000 | $-78,000,000 | $-483,000,000 | $-560,100,000 |
| Net Margin | 7.6% | -27.9% | -1.8% | -10.1% | -17.1% |
| EPS | $0.68 | $-2.50 | $-0.15 | $-0.97 | $-1.27 |
Company Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
58%
Hold / Neutral
4
33%
Sell / Underperform
1
8%
Analyst Consensus🟡 Mixed
7 Bullish5 Neutral/Bearish
Price Targets
$20
Average Target
↓ 9.5% Downside
Now
$14
Low
$20
Average
$30
High
Based on 17 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $30 |
| November 21st 2025 | KeyBanc Capital Markets | Initiation | Overweight | $27 |
| November 19th 2025 | Argus | Upgrade | Buy | $25 |
| October 7th 2025 | JP Morgan | Upgrade | Overweight | $24 |
| July 17th 2025 | Leerink Partners | Upgrade | Outperform | $18 |
| June 26th 2025 | William Blair | Upgrade | Outperform | - |
| December 9th 2024 | UBS | Initiation | Buy | $18 |
| December 2nd 2024 | Leerink Partners | Initiation | Market Perform | $14 |
| September 19th 2024 | Morgan Stanley | Downgrade | Equal Weight | $15← $17 |
| January 5th 2024 | Stifel | Upgrade | Buy | $20← $13 |
| December 19th 2023 | Jefferies | Initiation | Buy | $17 |
| December 15th 2023 | Morgan Stanley | Upgrade | Overweight | $16 |
| December 7th 2023 | Exane BNP Paribas | Initiation | Outperform | $18 |
| April 20th 2023 | Barclays | Upgrade | Overweight | $14 |
| August 18th 2022 | Morgan Stanley | Downgrade | Equal Weight | $22← $37 |
Earnings History & Surprises
ELANBeat Rate
89%
Last 18 quarters
Avg Surprise
+35.6%
EPS vs Estimate
Beats / Misses
16/2
Last 12 quarters
Latest EPS
$0.19
Q4 2025
EPS Surprise History
Q1 24
-20.0%
$0.08vs$0.10
Q2 24
+24.1%
$0.34vs$0.27
Q3 24
+25.0%
$0.30vs$0.24
Q4 24
+8.3%
$0.13vs$0.12
Q1 25
-12.5%
$0.14vs$0.16
Q2 25
+19.4%
$0.37vs$0.31
Q3 25
+30.0%
$0.26vs$0.20
Q4 25
+46.2%
$0.19vs$0.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 24, 2026 | $0.11 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.13 | $0.19 | +46.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.20 | $0.26 | +30.0% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $0.31 | $0.37 | +19.4% | ✓ BEAT |
Q1 2025 | Feb 25, 2025 | $0.16 | $0.14 | -12.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $0.12 | $0.13 | +8.3% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $0.24 | $0.30 | +25.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.27 | $0.34 | +24.1% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $0.10 | $0.08 | -20.0% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $0.12 | $0.18 | +50.0% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $0.05 | $0.18 | +260.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $0.29 | $0.45 | +55.2% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $0.13 | $0.19 | +46.2% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $0.16 | $0.20 | +25.0% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $0.26 | $0.36 | +38.5% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $0.35 | $0.36 | +2.9% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $0.17 | $0.21 | +23.5% | ✓ BEAT |
Q4 2021 | Nov 5, 2021 | $0.17 | $0.19 | +11.8% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $0.26 | $0.28 | +7.7% | ✓ BEAT |
Latest News
Morgan Stanley Maintains Equal-Weight on Elanco Animal Health, Raises Price Target to $22
📈 PositiveBenzinga•Dec 18, 2025, 05:46 PM
Elanco Receives FDA Conditional Approval For Credelio Quattro-CA1, Expanding Treatment Options For New World Screwworm In Companion Animals
📈 PositiveBenzinga•Dec 18, 2025, 01:44 PM
Barclays Initiates Coverage On Elanco Animal Health with Overweight Rating, Announces Price Target of $30
📈 PositiveBenzinga•Dec 9, 2025, 03:42 PM•Also:
Elanco Animal Health Expects $200M-$250M In Adj. EBITDA Savings From Elanco Ascend By 2030; Co Expects Innovation Revenue Contribution Of ~$1.1B In 2026
📈 PositiveBenzinga•Dec 9, 2025, 12:47 PM
Elanco Animal Health shares are trading higher after the company secured Emergency Use Authorization from the FDA for Credelio CAT to treat New World screwworm infestations in cats.
📈 PositiveBenzinga•Nov 21, 2025, 08:42 PM
Elanco Animal Health Receives Emergency Use Authorization From The FDA For Credelio Cat To Treat New World Screwworm Infestations In Cats
📈 PositiveBenzinga•Nov 21, 2025, 06:40 PM
Keybanc Initiates Coverage On Elanco Animal Health with Overweight Rating, Announces Price Target of $27
📈 PositiveBenzinga•Nov 21, 2025, 10:28 AM
Alloy Partners Launches OneHealth Studio, A Venture Studio Developed With Elanco Animal Health, To Build And Scale Companies Uniting Animal, Plant, And Human Health Innovations.
📈 PositiveBenzinga•Nov 13, 2025, 01:05 PM
UBS Maintains Buy on Elanco Animal Health, Raises Price Target to $27
📈 PositiveBenzinga•Nov 6, 2025, 05:35 PM
ELAN stock has given up its prior gain. Elanco Animal Health shares were trading higher after the company beat Q3 earnings and revenue estimates and raised its full-year EPS and sales guidance.
➖ NeutralBenzinga•Nov 5, 2025, 03:19 PM
Elanco Animal Health shares are trading higher after the company beat Q3 earnings and revenue estimates and raised its full-year EPS and sales guidance.
📈 PositiveBenzinga•Nov 5, 2025, 12:24 PM
Elanco Animal Health Sees Q4 GAAP EPS $(0.20)-$(0.17) vs $(0.05) Est
📉 NegativeBenzinga•Nov 5, 2025, 11:35 AM
Elanco Animal Health Sees Q4 2025 Adj EPS $0.09-$0.12 vs $0.14 Est; Sees Sales $1.085B-$1.110B vs $1.078B Est
➖ NeutralBenzinga•Nov 5, 2025, 11:33 AM
Elanco Animal Health Lowers FY2025 GAAP EPS Guidance from $(0.08)-$(0.03) to $(0.11)-$(0.08) vs $(0.03) Est
📉 NegativeBenzinga•Nov 5, 2025, 11:31 AM
Elanco Animal Health Raises FY2025 Adj EPS Guidance from $0.85-$0.91 to $0.91-$0.94 vs $0.90 Est; Raises FY2025 Sales Guidance from $4.570B-$4.620B to $4.645B-$4.670B vs $4.603B Est
📈 PositiveBenzinga•Nov 5, 2025, 11:30 AM
Elanco Animal Health Q3 Adj. EPS $0.19 Beats $0.13 Estimate, Sales $1.137B Beat $1.092B Estimate
📈 PositiveBenzinga•Nov 5, 2025, 11:28 AM
Elanco Animal Health Announces Label Expansions For Credelio Quattro And Credelio, With Product Labels Updated To Include Protection Against Lyme Disease And Emerging Tick Species
📈 PositiveBenzinga•Oct 27, 2025, 10:31 AM
Elanco Animal Health Receives Emergency Use Authorization From The FDA For Credelio To Treat New World Screwworm Infestations In Dogs
📈 PositiveBenzinga•Oct 24, 2025, 08:58 PM
UBS Maintains Buy on Elanco Animal Health, Raises Price Target to $25
📈 PositiveBenzinga•Oct 20, 2025, 10:19 PM
ELAN stock has given up its prior gain. Elanco Animal Health shares were trading higher after JP Morgan upgraded the stock from Neutral to Overweight and raised its price target from $18 to $24.
📈 PositiveBenzinga•Oct 7, 2025, 06:18 PM•Also:
Frequently Asked Questions about ELAN
What is ELAN's current stock price?
Elanco Animal Health Incorporated (ELAN) is currently trading at $22.30 per share. The stock has moved +0.95% today.
What is the analyst price target for ELAN?
The average analyst price target for ELAN is $26.00, based on 1 analyst.
What sector is Elanco Animal Health Incorporated in?
Elanco Animal Health Incorporated operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.
What is ELAN's market cap?
Elanco Animal Health Incorporated has a market capitalization of $11.08 billion, making it a large-cap company.
Does ELAN pay dividends?
No, Elanco Animal Health Incorporated does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALGN
Align Technology, Inc.
$157.69
Mkt Cap: $11.3B
EHC
Encompass Health Corporation
$106.39
Mkt Cap: $10.7B
ENSG
The Ensign Group, Inc.
$181.39
Mkt Cap: $10.4B
NBIX
Neurocrine Biosciences, Inc.
$145.00
Mkt Cap: $14.4B
QGEN
Qiagen N.V.
$45.58
Mkt Cap: $9.9B
RDY
Dr. Reddy's Laboratories Limited
$14.18
Mkt Cap: $11.8B
RVMD
Revolution Medicines, Inc.
$78.78
Mkt Cap: $15.2B
RVTY
Revvity, Inc.
$96.24
Mkt Cap: $11.4B
SOLV
Solventum Corporation
$81.59
Mkt Cap: $14.2B
VTRS
Viatris Inc.
$11.93
Mkt Cap: $13.7B
Explore stocks similar to ELAN for comparison